Urol. praxi. 2021;22(4):166-171 | DOI: 10.36290/uro.2021.021

Therapy of postradiation cystitis

MUDr. Mgr. Jaroslav Porš
Urologická ambulance a chirurgické oddělení Panochovy nemocnice Turnov

Postradiation cystitis is caused radiotherapy of onkological diseases in pelvis minor region. Mainly it's manifested by the lost of detrusor function, overactive bladder symptoms and haematurias. The treatment of these symptoms is very difficult. The article clearly discusses about possibilities of conservative and surgical treatment of this diagnosis.

Keywords: postradiation cystitis, radiotherapy, complications.

Received: May 10, 2021; Revised: May 10, 2021; Accepted: May 19, 2021; Prepublished online: May 19, 2021; Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Porš J. Therapy of postradiation cystitis. Urol. praxi. 2021;22(4):166-171. doi: 10.36290/uro.2021.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Soumarová R. Pokroky v radikální radioterapii u nádorů prostaty. In: Matoušková M, Svoboda T. Multimodální přístup k nádorům močového měchýře a prostaty. Olomouc: Solen 2017: 174-180.
    2. Macík D, Staník M, Doležal J. Léčba urologických komplikací spojených s ozářením karcinomu prostaty. Urol. praxi 2011; 12(5): 295-297.
    3. Krhut J. Hyperaktivní močový měchýř. Praha: Maxdorf Jessenius 2011: 90-91.
    4. Poršová M. Propiverin a účinná léčba příznaků hyperaktivního močového měchýře u dětí a dospělých. Urol. praxi 2007; 8(6): 294-296.
    5. Ryšánková M. Perspektivy léčby syndromu hyperaktivního močového měchýře. Urol. praxi 2019; 20(3): 102-107. Go to original source...
    6. Verner P. Porovnání účinnosti a vedlejších účinků anticholinergik při léčbě OAB. Urol. praxi 2010; 11(5): 241-246.
    7. El-Zawahry A. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB). Curr Urol Rep 2019; 20(6): 33. Go to original source... Go to PubMed...
    8. Yoshida M, Takeda M, Gotoh M, et al. Efficacy of novel β3 - adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. Int J Urol 2019; 26(3): 369-375. Go to original source... Go to PubMed...
    9. Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial. Eur Urol 2019; 75(2): 274-282. Go to original source... Go to PubMed...
    10. Slíva J. Fixní kombinace hyaluronátu s chondroitin sulfátem u recidivujících cystitid. Urol. praxi 2017; 18(5): 223-226. Go to original source...
    11. Gacci M, Saleh O, Giannessi C, et al. Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Im proves Symptoms of Postradiation Cystitis: Prospective Pilot Study. Clin Genitourin. Cancer 2016; 14: 444-449. Go to original source... Go to PubMed...
    12. Leippold T, et al. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003; 44: 165-174. Go to original source... Go to PubMed...
    13. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312. Go to original source... Go to PubMed...
    14. Šámal V. Botulinumtoxin a jeho aktuální možnosti použití v urologii. Ces Urol 2009; 13(3): 199-206.
    15. Ghei M, Marai BH, Miller R, et al. Effects of botulinum toxin BoNT/A on refraktory detrusor overactivity: a randomised, double blind, placebo-controlled, crossover trial. J Urol 2005; 174: 1873-1878. Go to original source... Go to PubMed...
    16. Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M. Botulinum Toxin A Versus Placebo for Refractory Detru sor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study). Eur Urol 2012; 5. Go to original source... Go to PubMed...
    17. Krhut J. Hyperaktivní močový měchýř. Praha: Maxdorf Jessenius 2011: 116-121.
    18. Pisco JM, Martins JM, Correia MG. Internal iliac artery: Embolization to control hemorrhage from pelvic neoplasms. Radiology 1989; 172: 337-339. Go to original source... Go to PubMed...
    19. Tůma M, Hyršl L, Ouhrabková R. Embolizace vnitřních větví a. iliaca interna jako řešení nezvladatelného krvácení u inoperabilního nádoru močového měchýře. Urol. praxi 2012; 13(6): 267-268.
    20. Janík V, Pádr R, Hyršl L, et al. Embolizace krvácejících inoperabilních nádorů v malé pánvi. Ces Urol 2001; 5(1): 21-25.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.